Conduit Pharmaceuticals Inc. Regains Nasdaq Compliance
Conduit Pharmaceuticals (NASDAQ: CDT) has successfully regained compliance with Nasdaq's listing requirements, specifically the minimum bid price requirement and stockholders' equity requirement. The clinical-stage life science company will continue to be listed and traded on the Nasdaq Stock Market.
The Nasdaq Hearing Panel has implemented a one-year Discretionary Panel Monitor starting May 15, 2025, to ensure long-term compliance with listing requirements. During this monitoring period, CDT maintains the right to request a hearing if it receives any future delisting determination letters.
Conduit Pharmaceuticals (NASDAQ: CDT) ha ripristinato con successo la conformità ai requisiti di quotazione di Nasdaq, in particolare per quanto riguarda il prezzo minimo delle azioni e il patrimonio netto degli azionisti. L'azienda, attiva nel settore delle scienze della vita in fase clinica, continuerà a essere quotata e negoziata sul Nasdaq Stock Market.
Il Nasdaq Hearing Panel ha stabilito un monitoraggio discrezionale di un anno a partire dal 15 maggio 2025, per garantire il rispetto a lungo termine dei requisiti di quotazione. Durante questo periodo di monitoraggio, CDT mantiene il diritto di richiedere un'udienza qualora riceva future lettere di determinazione per la delisting.
Conduit Pharmaceuticals (NASDAQ: CDT) ha recuperado con éxito el cumplimiento de los requisitos de cotización de Nasdaq, específicamente en cuanto al precio mínimo de la oferta y el patrimonio neto de los accionistas. La empresa de ciencias de la vida en etapa clínica continuará cotizando y negociándose en el Nasdaq Stock Market.
El Panel de Audiencias de Nasdaq ha implementado un monitor discrecional de un año a partir del 15 de mayo de 2025 para asegurar el cumplimiento a largo plazo de los requisitos de cotización. Durante este período de monitoreo, CDT conserva el derecho a solicitar una audiencia si recibe futuras cartas de determinación de exclusión.
Conduit Pharmaceuticals (NASDAQ: CDT)는 최소 입찰 가격 요건과 주주 자본 요건을 포함한 나스닥 상장 요건을 성공적으로 충족하였습니다. 임상 단계의 생명과학 회사인 이 기업은 앞으로도 나스닥 증권거래소에 상장되어 거래될 예정입니다.
나스닥 심의 패널은 2025년 5월 15일부터 시작되는 1년간의 재량 패널 모니터링을 도입하여 장기적인 상장 요건 준수를 보장할 것입니다. 이 모니터링 기간 동안 CDT는 향후 상장폐지 결정 통지서를 받을 경우 청문회를 요청할 권리를 유지합니다.
Conduit Pharmaceuticals (NASDAQ : CDT) a réussi à se conformer aux exigences de cotation du Nasdaq, notamment en ce qui concerne le prix minimum de l'offre et les capitaux propres des actionnaires. Cette société de sciences de la vie en phase clinique continuera d'être cotée et négociée sur le Nasdaq Stock Market.
Le Nasdaq Hearing Panel a mis en place une surveillance discrétionnaire d'un an à partir du 15 mai 2025, afin de garantir une conformité à long terme aux exigences de cotation. Pendant cette période de surveillance, CDT conserve le droit de demander une audience en cas de réception de futures lettres de décision de radiation.
Conduit Pharmaceuticals (NASDAQ: CDT) hat erfolgreich die Einhaltung der Nasdaq-Listenanforderungen, insbesondere der Mindestgebotspreis- und Eigenkapitalanforderungen, wiederhergestellt. Das klinisch orientierte Life-Science-Unternehmen wird weiterhin an der Nasdaq-Börse gelistet und gehandelt.
Das Nasdaq Hearing Panel hat eine einjährige diskretionäre Überwachung ab dem 15. Mai 2025 eingeführt, um die langfristige Einhaltung der Listenanforderungen sicherzustellen. Während dieses Überwachungszeitraums behält sich CDT das Recht vor, eine Anhörung anzufordern, falls zukünftige Delisting-Bescheide eingehen.
- Regained compliance with Nasdaq's minimum bid price requirement
- Regained compliance with stockholders' equity requirement
- Continued listing on Nasdaq maintained
- Company placed under one-year Discretionary Panel Monitor by Nasdaq
- Risk of future non-compliance and potential delisting remains
- Conduit regains compliance with Bid Price and Equity Requirements
- CDT will continue to be listed and traded on The Nasdaq Stock Market
NAPLES, Fla. and CAMBRIDGE, United Kingdom, May 21, 2025 (GLOBE NEWSWIRE) -- Conduit Pharmaceuticals Inc. (Nasdaq: CDT) (“Conduit” or the “Company”), a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development, announced that the Company received formal notice from The Nasdaq Stock Market LLC (“Nasdaq”) that the Company has regained compliance with Nasdaq’s minimum bid price requirement (the “Bid Price Requirement”) set forth in Nasdaq Listing Rule 5550(a)(2), as well as Nasdaq’s stockholders’ equity requirement (“Equity Requirement”) set forth in Nasdaq Listing Rule 5550(b)(1). The Company’s securities will continue to be listed and traded on The Nasdaq Stock Market.
The Hearing Panel has determined to impose a Discretionary Panel Monitor under Listing Rule 5815(d)(4)(A) for a period of one year from May 15, 2025, to ensure that the Company demonstrates long-term compliance with Nasdaq’s continued listing requirements. During this period the Company retains the right to request a hearing before the Panel in the event it receives a further Delist Determination Letter should it fall outside of compliance with any of Nasdaq’s continued listing requirements.
About Conduit Pharmaceuticals
Conduit is a dynamic, multi-asset clinical stage, life science company delivering an efficient model for compound development. Conduit both acquires and funds the development of Phase 2-ready assets, building an integrated and advanced platform-driven approached powered by artificial intelligence (AI) and cybernetics, and seeking an exit through third-party license deals following successful clinical trials. Led by a highly experienced team of executives including Dr. Andrew Regan and Dr. Freda Lewis-Hall, this novel approach is a departure from the traditional pharma/biotech business model of taking assets through regulatory approval.
Cautionary Statement Regarding Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts contained in this press release, including statements regarding Conduit’s future results of operations and financial position, Conduit’s business strategy, prospective product candidates, product approvals, research and development costs, timing and likelihood of success, plans and objectives of management for future operations, future results of current and anticipated studies and business endeavors with third parties, and future results of current and anticipated product candidates, are forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions. These forward-looking statements are subject to a number of risks, uncertainties and assumptions, including, but not limited to: the effect that the reverse stock split may have on the price of the Company’s common stock; the ability or inability to maintain the listing of Conduit’s securities on Nasdaq; the ability to recognize the anticipated benefits of the business combination completed in September 2023, which may be affected by, among other things, competition; the ability of the combined company to grow and manage growth economically and hire and retain key employees; the risks that Conduit’s product candidates in development fail clinical trials or are not approved by the U.S. Food and Drug Administration or other applicable authorities on a timely basis or at all; changes in applicable laws or regulations; the possibility that Conduit may be adversely affected by other economic, business, and/or competitive factors; and other risks as identified in filings made by Conduit with the U.S. Securities and Exchange Commission. Moreover, Conduit operates in a very competitive and rapidly changing environment. Because forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted or quantified and some of which are beyond Conduit’s control, you should not rely on these forward-looking statements as predictions of future events. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and except as required by law, Conduit assumes no obligation and does not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. Conduit gives no assurance that it will achieve its expectations.
Investors
Conduit Pharmaceuticals Inc.
info@conduitpharma.com
FAQ
What did Conduit Pharmaceuticals (CDT) announce regarding Nasdaq compliance on May 21, 2025?
How long will CDT be under Nasdaq's Discretionary Panel Monitor?
What happens if CDT fails to meet Nasdaq requirements during the monitoring period?
Which specific Nasdaq listing rules did Conduit Pharmaceuticals regain compliance with?
